Recombinant Human Matriptase/ST14 Catalytic Domain, CF 3946-SEB-010 from R&D Systems, a Bio-Techne Brand

Product Specs
ItemRecombinant Human Matriptase/ST14 Catalytic Domain, CF
CompanyR&D Systems, a Bio-Techne Brand
Price $527.00Supplier Page View Company Product Page
Catalog Number3946-SEB-010
Size10 ug
ApplicationsEnzyme Activity
Conjugate/TagUnconjugated
Purity>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
Molecular WeightObserved: 27 kDa (major) and minor auto-activation fragments, reducing conditions
Theoretical: 26 kDa
SpeciesHuman
Molecule NameMatriptase/ST14
NCBI Full Gene NameST14 transmembrane serine protease matriptase
NCBI Gene AliasesMT-SP1, HAI, PRSS14, CAP3, TADG15, SNC19, TMPRSS14, ARCI11, MTSP1
FormatSupplied as a 0.2 µm filtered solution in Tris-HCl and Glycerol
Source/Expression SystemE. coli-derived Recombinant Human Matriptase/ST14 Catalytic Domain, CF
StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. 6 months from date of receipt, -20 to -70 °C as supplied. 3 months, -20 to -70 °C under sterile conditions after opening

Add to Compare List

R&D Systems, a Bio-Techne Brand

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

Company Profile

Website: http://www.rndsystems.com

(1) Monoclonal antibody inhibition of PAR2 reduces phenotype severity and pain in murine inflammatory bowel diseasePain RepApril 20, 2026Anne Ritoux, Laura J. Grundy, Pravallika Manjappa, Luke W. Paine, Jessica Neisen, John E. Linley, Ewan St. John Smithcontrol antibodies, for 60 minutes at room temperature before addition of PAR2 activating matriptase34 (3946-SEB-010, R&D Systems, Abingdon, United Kingdom). 2.12. Statistical analysis Statistical analyses were conducted

(2) Impact of tumor localization on antitumor immunity with conditionally activated CTLA-4 blockadeJ Immunother CancerApril 2, 2025Marcel Arias-Badia, Chien-Chun Steven Pai, Yee May Lwin, PeiXi Chen, Aahir Srinath, Miho Tanaka, Emily Musser, Andrew Goodearl, Jacob V Gorman, Wendy Ritacco, et al.was assessed by overnight incubation of 20 µg of each in the presence of 5 µL recombinant Matriptase (3946-SEB-010, BioTechne) at room temperature. Then, 3 µg lysates were prepared in NuPAGE LDS Sample Buffer (NP0007,

(3) First-generation high-affinity ST14 radiopharmaceutical: Design, synthesis, and preclinical PET imaging evaluation for pancreatic cancer detectionBioorganic chemistryJanuary 1, 2025Peng T, Wen J, Huang G, Zhao H, Liu J.

(4) Mechanism-Based Macrocyclic Inhibitors of Serine ProteasesJournal of Medicinal ChemistryMarch 28, 2024Vishnu C. Damalanka, Victoria Banas, Paolo De Bona, Maithri M. Kashipathy, Kevin Battaile, Scott Lovell, James W. JanetkaDMSO final concentration) and then mixed with recombinant HGFA (1514-SE-010, R&D Systems), matriptase (3946-SEB-010, R&D Systems), TMPRSS2 (CSB-YP023924HU, Cusabio Technology), or activated hepsin in black 384-well plates

(5) SARS-CoV-2 infection of human lung epithelial cells induces TMPRSS-mediated acute fibrin depositionNature communicationsOctober 11, 2023Erickson R, Huang C, Allen C, Ireland J, Roth G, Zou Z, Lu J, Lafont BAP, Garza NL, Brumbaugh B, et al.(R&D Systems, Inc. catalog 1063-SE-010) or 500 ng recombinant matriptase (R&D Systems, Inc. catalog 3946-SEB-010) or 200 ng of HAT (R&D Systems, Inc. catalog 2695-SE-010) in 40 µl volume in a 384-well plate at room

(6) Autophagy of Candida albicans cells after the action of earthworm Venetin-1 nanoparticle with protease inhibitor activityScientific reportsAugust 30, 2023Wójcik-Mieszawska S, Lewtak K, Skwarek E, Dębowski D, Gitlin-Domagalska A, Nowak J, Wydrych J, Pawelec J, Fiołka MJ.

(7) Insufficiency of hepatocyte growth factor activator inhibitor-1 confers lymphatic invasion of tongue carcinoma cellsCancer scienceJune 1, 2022Izumi A, Yamamoto K, Kawaguchi M, Yamashita F, Fukushima T, Kiwaki T, Tanaka H, Yamashita Y, Kataoka H.

(8) Engineering and Structural Insights of a Novel BBI-like Protease Inhibitor Livisin from the Frog Skin SecretionToxinsApril 12, 2022Yang J, Tong C, Qi J, Liao X, Li X, Zhang X, Zhou M, Wang L, Ma C, Xi X, et al.

(9) The activation fragment of PAR2 is elevated in serum from patients with rheumatoid arthritis and reduced in response to anti-IL6R treatmentScientific reportsDecember 20, 2021Kalogera S, He Y, Bay-Jensen AC, Gantzel T, Sun S, Manon-Jensen T, Karsdal MA, Thudium CS.H00002150-P01, Novus Biologicals, Centennial, Colorado, USA) and matriptase as the enzyme (cat.no. 3946-SEB-010, R&D systems, Minneapolis, Minnesota, USA,) was performed. Cleavage buffer for the reaction contained

(10) Novel Ex Vivo Zymography Approach for Assessment of Protease Activity in Tissues with Activatable AntibodiesPharmaceuticsSeptember 2, 2021Howng B, Winter MB, LePage C, Popova I, Krimm M, Vasiljeva O.

(11) Dexamethasone-Loaded Nanostructured Lipid Carriers for the Treatment of Dry Eye DiseasePharmaceuticsJune 18, 2021Kumari S, Dandamudi M, Rani S, Behaeghel E, Behl G, Kent D, O'Reilly NJ, O'Donovan O, McLoughlin P, Fitzhenry L.

(12) PAR2 Activation on Human Kidney Tubular Epithelial Cells Induces Tissue Factor Synthesis, That Enhances Blood ClottingFrontiers in physiologyJanuary 1, 2021Iyer A, Humphries TLR, Owens EP, Zhao KN, Masci PP, Johnson DW, Nikolic-Paterson D, Gobe GC, Fairlie DP, Vesey DA.(Translational Research Institute, The University of Queensland) or purchased from R&D Systems, Cat # 3946-SEB-010 (Minneapolis, MN, United states). Vorapaxar, Cat. No. 23119 was obtained from Cayman Chemicals (MI,

(13) Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibodyNature communicationsJune 24, 2020Geiger M, Stubenrauch KG, Sam J, Richter WF, Jordan G, Eckmann J, Hage C, Nicolini V, Freimoser-Grundschober A, Ritter M, et al.

(14) Blocking the proteolytic activity of zymogen matriptase with antibody-based inhibitorsThe Journal of biological chemistryJanuary 4, 2019Tamberg T, Hong Z, De Schepper D, Skovbjerg S, Dupont DM, Vitved L, Schar CR, Skjoedt K, Vogel LK, Jensen JK.

(15) Matriptase cleaves the amyloid-beta peptide 1-42 at Arg-5, Lys-16, and Lys-28BMC research notesJanuary 3, 2019Chen LM, Chai KX.text Methods Cleavage of Aβ1–42 by matriptase A recombinant human matriptase protease domain (MatPD, Cat. No. 3946-SEB-010) and a synthetic human Aβ1–42 peptide (Cat. No. 1428/100U) were purchased from Bio-Techne (Minneapolis,

(16) A peptide-based approach to evaluate the adaptability of influenza A virus to humans based on its hemagglutinin proteolytic cleavage sitePloS oneJanuary 1, 2017Straus MR, Whittaker GR.

(17) A Selective Irreversible Inhibitor of Furin Does Not Prevent Pseudomonas Aeruginosa Exotoxin A-Induced Airway Epithelial CytotoxicityPloS oneJanuary 1, 2016Ferguson TE, Reihill JA, Walker B, Hamilton RA, Martin SL.

(18) The HIV-1 gp41 ectodomain is cleaved by matriptase to produce a chemotactic peptide that acts through FPR2ImmunologyJuly 1, 2014Wood MP, Cole AL, Eade CR, Chen LM, Chai KX, Cole AM.

(19) High-affinity cyclic peptide matriptase inhibitorsThe Journal of biological chemistryMay 10, 2013Quimbar P, Malik U, Sommerhoff CP, Kaas Q, Chan LY, Huang YH, Grundhuber M, Dunse K, Craik DJ, Anderson MA, et al.

(20) Simukunin from the salivary glands of the black fly Simulium vittatum inhibits enzymes that regulate clotting and inflammatory responsesPloS oneJanuary 1, 2012Tsujimoto H, Kotsyfakis M, Francischetti IM, Eum JH, Strand MR, Champagne DE.

Be the First to Write a Review!

Matriptase/ST14 Catalytic Domain Protein

Matriptase/ST14 Catalytic Domain Protein

Matriptase/ST14 Catalytic Domain Protein

Recombinant Human Matriptase/ST14 Catalytic Domain, CF from R&D Systems, a Bio-Techne Brand

R&D Systems, a Bio-Techne Brand

Citations (23)

Reviews

Recombinant Human Matriptase/ST14 Catalytic Domain, CF from R&D Systems, a Bio-Techne Brand

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map